Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05946941




Registration number
NCT05946941
Ethics application status
Date submitted
7/07/2023
Date registered
14/07/2023
Date last updated
31/10/2024

Titles & IDs
Public title
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
Scientific title
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome (POETYK SjS-1)
Secondary ID [1] 0 0
2023-503327-26
Secondary ID [2] 0 0
IM011-1069
Universal Trial Number (UTN)
Trial acronym
POETYK SjS-1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Sjögren's Syndrome 0 0
Condition category
Condition code
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders
Inflammatory and Immune System 0 0 0 0
Autoimmune diseases
Other 0 0 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Deucravacitinib
Other interventions - Placebo

Experimental: Deucravacitinib, Dose 1 -

Experimental: Deucravacitinib, Dose 2 -

Placebo comparator: Placebo, followed by Deucravacitinib Dose 1 or Dose 2 -


Treatment: Drugs: Deucravacitinib
Specified dose on specified days

Other interventions: Placebo
Specified dose on specified days
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change from baseline in European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 52
Timepoint [1] 0 0
Baseline, Week 52
Secondary outcome [1] 0 0
Change from baseline in European League Against Rheumatism Sjögren's Syndrome Patient Reported Index (ESSPRI) Score at Week 52
Timepoint [1] 0 0
Baseline, Week 52
Secondary outcome [2] 0 0
Number of participants with decrease in ESSPRI = 1 or 15% from baseline at Week 52
Timepoint [2] 0 0
Baseline, Week 52
Secondary outcome [3] 0 0
Number of participants with decrease in ESSDAI = 3 points from baseline at Week 52
Timepoint [3] 0 0
Baseline, Week 52
Secondary outcome [4] 0 0
Number of participants with ESSDAI < 5 at Week 52
Timepoint [4] 0 0
Baseline, Week 52
Secondary outcome [5] 0 0
Change from baseline in ESSDAI at Week 24
Timepoint [5] 0 0
Baseline, Week 24
Secondary outcome [6] 0 0
Change from baseline in stimulated whole salivary flow (SWSF) at Week 52
Timepoint [6] 0 0
Baseline, Week 52
Secondary outcome [7] 0 0
Change from baseline in physician global assessment (PhGA) at Week 52
Timepoint [7] 0 0
Baseline, Week 52
Secondary outcome [8] 0 0
Change from baseline in functional assessment of chronic illness therapy (FACIT)-fatigue at Week 52
Timepoint [8] 0 0
Baseline, Week 52
Secondary outcome [9] 0 0
Change from baseline in ocular dryness numeric rating scale (NRS) at Week 52
Timepoint [9] 0 0
Baseline, Week 52
Secondary outcome [10] 0 0
Change from baseline in oral dryness NRS at Week 52
Timepoint [10] 0 0
Baseline, Week 52
Secondary outcome [11] 0 0
Change from baseline in joint/ muscle pain NRS at Week 52
Timepoint [11] 0 0
Baseline, Week 52
Secondary outcome [12] 0 0
Number of participants with adverse events (AEs)
Timepoint [12] 0 0
Up to Week 160
Secondary outcome [13] 0 0
Number of participants with serious AEs (SAEs)
Timepoint [13] 0 0
Up to Week 160
Secondary outcome [14] 0 0
Number of participants with AEs leading to discontinuation of treatment and study discontinuation
Timepoint [14] 0 0
Up to Week 160
Secondary outcome [15] 0 0
Number of participants with AEs of special interest (AESIs)
Timepoint [15] 0 0
Up to Week 160
Secondary outcome [16] 0 0
Number of participants with clinical laboratory abnormalities
Timepoint [16] 0 0
Up to Week 160
Secondary outcome [17] 0 0
Number of participants with electrocardiogram (ECG) abnormalities
Timepoint [17] 0 0
Up to Week 156
Secondary outcome [18] 0 0
Number of participants with vital sign abnormalities
Timepoint [18] 0 0
Up to Week 160

Eligibility
Key inclusion criteria
Inclusion Criteria

* Satisfy the 2016 American College of Rheumatology/European League Against Rheumatism criteria for the classification of SjS with disease duration (from time of diagnosis) of at least 16 weeks prior to screening.
* Have moderate to severe SjS ESSDAI = 5.
* Short duration of disease (= 10 years) before screening.
* A stimulated whole salivary flow (SWSF) = 0.05 mililiters/minute (mL/minute).
* Positive anti-Sjögren's syndrome-associated antigen A (anti-Ro/SSA) at screening.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

* Autoimmune disease other than SjS (for example, rheumatoid arthritis, systemic lupus erthrematosus [SLE], systemic sclerosis).
* Active fibromyalgia with pain symptoms or signs that would interfere with joint assessment or requiring adjustment in medication within the 3 months before screening to control symptoms; participants with fibromyalgia that is well controlled on stable treatment may otherwise be considered.
* Medical condition associated with sicca syndrome.
* Previous exposure to tyrosine kinase 2 (TYK2) inhibitors such as deucravacitinib or related compounds.
* Other protocol-defined Inclusion/Exclusion criteria apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
11/09/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
16/11/2028
Actual
Sample size
Target
756
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA,WA
Recruitment hospital [1] 0 0
The Queen Elizabeth Hospital - Woodville South
Recruitment hospital [2] 0 0
Local Institution - 0165 - Nedlands
Recruitment postcode(s) [1] 0 0
5011 - Woodville South
Recruitment postcode(s) [2] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Kansas
Country [7] 0 0
United States of America
State/province [7] 0 0
Kentucky
Country [8] 0 0
United States of America
State/province [8] 0 0
Louisiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Minnesota
Country [12] 0 0
United States of America
State/province [12] 0 0
New Jersey
Country [13] 0 0
United States of America
State/province [13] 0 0
New Mexico
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
Oregon
Country [16] 0 0
United States of America
State/province [16] 0 0
Pennsylvania
Country [17] 0 0
United States of America
State/province [17] 0 0
Tennessee
Country [18] 0 0
United States of America
State/province [18] 0 0
Texas
Country [19] 0 0
United States of America
State/province [19] 0 0
Washington
Country [20] 0 0
Argentina
State/province [20] 0 0
Alabama
Country [21] 0 0
Argentina
State/province [21] 0 0
Buenos Aires
Country [22] 0 0
Argentina
State/province [22] 0 0
General Paz
Country [23] 0 0
Argentina
State/province [23] 0 0
Tucuman
Country [24] 0 0
Argentina
State/province [24] 0 0
Caba
Country [25] 0 0
Argentina
State/province [25] 0 0
City of Buenos Aires
Country [26] 0 0
Argentina
State/province [26] 0 0
Cordoba
Country [27] 0 0
Austria
State/province [27] 0 0
Graz
Country [28] 0 0
Austria
State/province [28] 0 0
Wien
Country [29] 0 0
Belgium
State/province [29] 0 0
Aalst
Country [30] 0 0
Belgium
State/province [30] 0 0
Gent
Country [31] 0 0
Brazil
State/province [31] 0 0
ES
Country [32] 0 0
Brazil
State/province [32] 0 0
MG
Country [33] 0 0
Brazil
State/province [33] 0 0
Minas Gerais
Country [34] 0 0
Brazil
State/province [34] 0 0
RS
Country [35] 0 0
Brazil
State/province [35] 0 0
SP
Country [36] 0 0
Brazil
State/province [36] 0 0
Uberlandia
Country [37] 0 0
Bulgaria
State/province [37] 0 0
Plovdiv
Country [38] 0 0
Bulgaria
State/province [38] 0 0
Sofia
Country [39] 0 0
Canada
State/province [39] 0 0
British Columbia
Country [40] 0 0
Canada
State/province [40] 0 0
Ontario
Country [41] 0 0
Canada
State/province [41] 0 0
Quebec
Country [42] 0 0
Chile
State/province [42] 0 0
Los Rios
Country [43] 0 0
Chile
State/province [43] 0 0
Metropolitana
Country [44] 0 0
Chile
State/province [44] 0 0
Providencia
Country [45] 0 0
Chile
State/province [45] 0 0
Region Metropolitana
Country [46] 0 0
Chile
State/province [46] 0 0
Osorno
Country [47] 0 0
Chile
State/province [47] 0 0
Santiago
Country [48] 0 0
Chile
State/province [48] 0 0
Vina del Mar
Country [49] 0 0
China
State/province [49] 0 0
Beijing
Country [50] 0 0
China
State/province [50] 0 0
Chongqing
Country [51] 0 0
China
State/province [51] 0 0
Fujian
Country [52] 0 0
China
State/province [52] 0 0
Guangdong
Country [53] 0 0
China
State/province [53] 0 0
Henan
Country [54] 0 0
China
State/province [54] 0 0
Hubei
Country [55] 0 0
China
State/province [55] 0 0
Hunan
Country [56] 0 0
China
State/province [56] 0 0
Inner Mongolia
Country [57] 0 0
China
State/province [57] 0 0
Jiangsu
Country [58] 0 0
China
State/province [58] 0 0
Jiangxi
Country [59] 0 0
China
State/province [59] 0 0
Shaanxi
Country [60] 0 0
China
State/province [60] 0 0
Shanghai Sheng
Country [61] 0 0
China
State/province [61] 0 0
Shanghai
Country [62] 0 0
China
State/province [62] 0 0
Shanxi
Country [63] 0 0
China
State/province [63] 0 0
Sichuan
Country [64] 0 0
China
State/province [64] 0 0
Xinjiang Sheng
Country [65] 0 0
China
State/province [65] 0 0
Zhejiang
Country [66] 0 0
Colombia
State/province [66] 0 0
Atlantico
Country [67] 0 0
Colombia
State/province [67] 0 0
Cundinamarca
Country [68] 0 0
Colombia
State/province [68] 0 0
Bogota D.C
Country [69] 0 0
Denmark
State/province [69] 0 0
Region Midt
Country [70] 0 0
Denmark
State/province [70] 0 0
Glostrup
Country [71] 0 0
Finland
State/province [71] 0 0
Helsinki
Country [72] 0 0
Finland
State/province [72] 0 0
Kuopio
Country [73] 0 0
Finland
State/province [73] 0 0
Turku
Country [74] 0 0
France
State/province [74] 0 0
Cedex 13
Country [75] 0 0
France
State/province [75] 0 0
Centre
Country [76] 0 0
France
State/province [76] 0 0
Amiens
Country [77] 0 0
France
State/province [77] 0 0
Bordeaux
Country [78] 0 0
France
State/province [78] 0 0
Grenoble
Country [79] 0 0
France
State/province [79] 0 0
Le Havre Cedex
Country [80] 0 0
France
State/province [80] 0 0
Le Kremlin-Bictre
Country [81] 0 0
France
State/province [81] 0 0
Marseille
Country [82] 0 0
France
State/province [82] 0 0
Paris
Country [83] 0 0
Germany
State/province [83] 0 0
Bayern
Country [84] 0 0
Germany
State/province [84] 0 0
Berlin
Country [85] 0 0
Germany
State/province [85] 0 0
Freiburg
Country [86] 0 0
Germany
State/province [86] 0 0
Hamburg
Country [87] 0 0
Germany
State/province [87] 0 0
Tuebingen
Country [88] 0 0
Germany
State/province [88] 0 0
Wuerzburg
Country [89] 0 0
Greece
State/province [89] 0 0
Athens
Country [90] 0 0
Greece
State/province [90] 0 0
Athina
Country [91] 0 0
Greece
State/province [91] 0 0
Larissa
Country [92] 0 0
Hungary
State/province [92] 0 0
Válassz Egy Opciót…
Country [93] 0 0
Hungary
State/province [93] 0 0
Budapest
Country [94] 0 0
Hungary
State/province [94] 0 0
Debrecen
Country [95] 0 0
Hungary
State/province [95] 0 0
Gyula
Country [96] 0 0
Israel
State/province [96] 0 0
IA
Country [97] 0 0
Israel
State/province [97] 0 0
Kfar Sava
Country [98] 0 0
Italy
State/province [98] 0 0
Brescia
Country [99] 0 0
Italy
State/province [99] 0 0
Milano
Country [100] 0 0
Italy
State/province [100] 0 0
Napoli
Country [101] 0 0
Italy
State/province [101] 0 0
Padua
Country [102] 0 0
Italy
State/province [102] 0 0
Pisa
Country [103] 0 0
Italy
State/province [103] 0 0
Rome
Country [104] 0 0
Italy
State/province [104] 0 0
Udine
Country [105] 0 0
Japan
State/province [105] 0 0
Aichi
Country [106] 0 0
Japan
State/province [106] 0 0
Fukuoka
Country [107] 0 0
Japan
State/province [107] 0 0
Hokkaido
Country [108] 0 0
Japan
State/province [108] 0 0
Hyogo
Country [109] 0 0
Japan
State/province [109] 0 0
Ibaraki
Country [110] 0 0
Japan
State/province [110] 0 0
Ishikawa
Country [111] 0 0
Japan
State/province [111] 0 0
Kanagawa
Country [112] 0 0
Japan
State/province [112] 0 0
Miyagi
Country [113] 0 0
Japan
State/province [113] 0 0
Nagasaki
Country [114] 0 0
Japan
State/province [114] 0 0
Okayama
Country [115] 0 0
Japan
State/province [115] 0 0
Shiga
Country [116] 0 0
Japan
State/province [116] 0 0
Shizuoka
Country [117] 0 0
Japan
State/province [117] 0 0
Tochigi
Country [118] 0 0
Japan
State/province [118] 0 0
Tokyo
Country [119] 0 0
Korea, Republic of
State/province [119] 0 0
Seoul
Country [120] 0 0
Korea, Republic of
State/province [120] 0 0
Gwangju
Country [121] 0 0
Mexico
State/province [121] 0 0
Distrito Federal
Country [122] 0 0
Mexico
State/province [122] 0 0
Guanajuato
Country [123] 0 0
Mexico
State/province [123] 0 0
Jalisco
Country [124] 0 0
Mexico
State/province [124] 0 0
Chihuahua
Country [125] 0 0
Netherlands
State/province [125] 0 0
Friesland
Country [126] 0 0
Netherlands
State/province [126] 0 0
Zuid-Holland
Country [127] 0 0
Netherlands
State/province [127] 0 0
Groningen
Country [128] 0 0
Peru
State/province [128] 0 0
Lima
Country [129] 0 0
Poland
State/province [129] 0 0
Malopolskie
Country [130] 0 0
Poland
State/province [130] 0 0
Mazowieckie
Country [131] 0 0
Poland
State/province [131] 0 0
Woj. Mazowieckie
Country [132] 0 0
Poland
State/province [132] 0 0
Bydgoszcz
Country [133] 0 0
Poland
State/province [133] 0 0
Lublin
Country [134] 0 0
Poland
State/province [134] 0 0
Poznan
Country [135] 0 0
Poland
State/province [135] 0 0
Warsawa
Country [136] 0 0
Poland
State/province [136] 0 0
Warsaw
Country [137] 0 0
Poland
State/province [137] 0 0
Warszawa
Country [138] 0 0
Poland
State/province [138] 0 0
Wroclaw
Country [139] 0 0
Portugal
State/province [139] 0 0
Lisboa
Country [140] 0 0
Puerto Rico
State/province [140] 0 0
San Juan
Country [141] 0 0
Romania
State/province [141] 0 0
Brasov
Country [142] 0 0
Romania
State/province [142] 0 0
Bucharest
Country [143] 0 0
Romania
State/province [143] 0 0
Cluj-Napoca
Country [144] 0 0
Romania
State/province [144] 0 0
Iasi
Country [145] 0 0
Spain
State/province [145] 0 0
Badajoz
Country [146] 0 0
Spain
State/province [146] 0 0
Cantabria
Country [147] 0 0
Spain
State/province [147] 0 0
Santa Cruz De Tenerife
Country [148] 0 0
Spain
State/province [148] 0 0
A Coruna
Country [149] 0 0
Spain
State/province [149] 0 0
Santiago De Compostela
Country [150] 0 0
Spain
State/province [150] 0 0
Sevilla
Country [151] 0 0
Sweden
State/province [151] 0 0
Gotenburg
Country [152] 0 0
Sweden
State/province [152] 0 0
Solna
Country [153] 0 0
Switzerland
State/province [153] 0 0
Baden-Württemberg
Country [154] 0 0
Switzerland
State/province [154] 0 0
Bern
Country [155] 0 0
Switzerland
State/province [155] 0 0
Southwest
Country [156] 0 0
Taiwan
State/province [156] 0 0
Kaohsiung City
Country [157] 0 0
Taiwan
State/province [157] 0 0
Taichung
Country [158] 0 0
Taiwan
State/province [158] 0 0
Taipei City
Country [159] 0 0
Taiwan
State/province [159] 0 0
Taoyuan City
Country [160] 0 0
Turkey
State/province [160] 0 0
Ankara
Country [161] 0 0
Turkey
State/province [161] 0 0
Antalya
Country [162] 0 0
Turkey
State/province [162] 0 0
Istanbul
Country [163] 0 0
United Kingdom
State/province [163] 0 0
Hampshire
Country [164] 0 0
United Kingdom
State/province [164] 0 0
Tyne And Wear
Country [165] 0 0
United Kingdom
State/province [165] 0 0
West Midlands
Country [166] 0 0
United Kingdom
State/province [166] 0 0
Birmingham
Country [167] 0 0
United Kingdom
State/province [167] 0 0
Cannock

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bristol-Myers Squibb
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.
Trial website
https://clinicaltrials.gov/study/NCT05946941
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Address 0 0
Country 0 0
Phone 0 0
855-907-3286
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05946941